Evaluation of the Efficacy and Safety of the Dermal Filler for Augmentation of Labia Majora.

Inclusion Criteria: * Female subject aged ≥18; * Subject presenting vulvar ptosis, deflation or aesthetic discomfort in the intimate area; * Subject who presents no type of pathology of the area to be treated; * Subjects who are willing to abstain from any cosmetic or surgical procedures in the treatment area during the clinical investigation; * Clinically and anamnestically healthy individual; * Absence of a history of significant hypersensitivity to food and drugs or known sensitivity to hyaluronic acid; * Arterial blood pressure (BP) (after 5 min. at rest in the supine position) systolic 90 - 140 mmHg and diastolic 50 - 90 mmHg; * Heart rate (HR) (after 5 min. at rest in the supine position) over 50 beats/min and less than 90 beats/min; * Respiratory rate between 12 - 24 breaths/min; * Axillar body temperature of up to 370С; * Clinical-laboratory examinations within the reference ranges or with no clinically significant abnormalities; * Negative AIDS/HIV test; * Negative pregnancy test for the women with reproductive potential; * Reliable and acceptable method of contraception for the women of child-bearing potential * Signed written Informed Consent Form. Exclusion Criteria: * Subject with known sensitivity to hyaluronic acid or significant hypersensitivity to food and drugs; * Subject with history of vulvar cancer and/or previous regional radiotherapy; * Subjects with frequent or present active herpes simplex or herpes zoster local infection or active herpes simplex or herpes zoster infection in other sites; * Subjects with history of frequent or active local dermatitis (of the injection site), vulvar scaly papilloma, mycosis; bacterial infection; * Subjects suffering from autoimmune diseases or who are undergoing treatment with immunosuppressors or immunotherapy; * Subjects uncontrolled systemic diseases; * Pregnancy, postpartum period (6 months) or post-lactation period (6 months); * Absence of a reliable and effective method of contraception; * Subjects who are currently receiving another investigational treatment or who had participated in another clinical investigation within 30 days prior to study enrollment; * Subjects who suffer from another medical condition or who are receiving medication that in the Principal Investigator's judgment would prohibit inclusion in the study; * Subjects with limited mental activity and consistent comprehension ability; sportsmen and individuals on strenuous physical loading; prisoners; * Refusal to sign the Informed Consent Form.